This could be an interesting attempt at combining CAR T-cells with oncolytic viruses for the treatment of hematological malignancies but also for solid cancer, where one phase I trial is running using a binary oncolytic adenovirus and HER2-targeted CAR T-cells (NCT03740256) for the treatment of HER2 positive solid tumors. This evidence concerns the gene ERBB2 and hematologic disorder.